← Markets

Intuitive Surgical, Inc.

ISRG · NASDAQ

Low target$375.00
Average target$521.10
High target$685.00

Analyst ratings

strong_buy · 21 ratings

DateFirmActionRatingPrice target
July 17, 2026Raymond JamesMaintainsOutperform$483.00
July 17, 2026Piper SandlerReiteratesOverweight$470.00
July 17, 2026JP MorganMaintainsOverweight$450.00
July 17, 2026MizuhoMaintainsNeutral$400.00
July 17, 2026Wells FargoMaintainsOverweight$487.00
July 17, 2026TD CowenMaintainsBuy$485.00
July 17, 2026Evercore ISI GroupMaintainsIn-Line$375.00
July 17, 2026RBC CapitalMaintainsOutperform$575.00
July 17, 2026StifelMaintainsBuy$550.00
July 17, 2026CitigroupMaintainsBuy$500.00
July 17, 2026BernsteinMaintainsOutperform$685.00
July 17, 2026Leerink PartnersMaintainsOutperform$454.00
July 17, 2026BairdMaintainsOutperform$500.00
July 17, 2026BTIGMaintainsBuy$469.00
July 16, 2026Truist SecuritiesMaintainsBuy$510.00
July 15, 2026MizuhoMaintainsNeutral$500.00
July 13, 2026TD CowenMaintainsBuy$520.00
July 13, 2026RBC CapitalMaintainsOutperform$600.00
July 6, 2026Evercore ISI GroupMaintainsIn-Line$430.00
May 18, 2026B of A SecuritiesMaintainsBuy$520.00
April 23, 2026BarclaysMaintainsOverweight$651.00
April 22, 2026Leerink PartnersMaintainsOutperform$573.00
April 22, 2026BairdMaintainsOutperform$610.00
April 22, 2026Piper SandlerMaintainsOverweight$580.00
April 22, 2026BTIGReiteratesBuy$574.00
April 15, 2026Truist SecuritiesMaintainsBuy$580.00
April 13, 2026MizuhoMaintainsNeutral$525.00
April 10, 2026BTIGReiteratesBuy$616.00
April 9, 2026Goldman SachsMaintainsBuy$609.00
April 6, 2026Evercore ISI GroupMaintainsIn-Line$480.00
March 17, 2026UBSMaintainsNeutral$550.00
March 11, 2026CitigroupUpgradesBuy$590.00
February 24, 2026UBSMaintainsNeutral$570.00
January 27, 2026Freedom Capital MarketsUpgradesBuy$610.00
January 26, 2026BarclaysMaintainsOverweight$712.00
January 26, 2026Freedom BrokerUpgradesBuy$610.00
January 23, 2026CitigroupMaintainsNeutral$590.00
January 23, 2026Evercore ISI GroupMaintainsIn-Line$550.00
January 23, 2026Piper SandlerMaintainsOverweight$620.00
January 23, 2026BernsteinMaintainsOutperform$750.00
January 23, 2026BTIGReiteratesBuy$616.00
January 9, 2026BernsteinMaintainsOutperform$740.00
January 7, 2026BarclaysMaintainsOverweight$686.00
January 7, 2026BTIGMaintainsBuy$616.00
December 18, 2025Truist SecuritiesMaintainsBuy$650.00
December 17, 2025RBC CapitalMaintainsOutperform$650.00
December 11, 2025CitigroupDowngradesNeutral$635.00
October 28, 2025Freedom BrokerMaintainsBuy$560.00
October 23, 2025UBSMaintainsNeutral$600.00
October 22, 2025Raymond JamesMaintainsOutperform$603.00
October 22, 2025Piper SandlerReiteratesOverweight$610.00
October 22, 2025RBC CapitalMaintainsOutperform$625.00
October 22, 2025Truist SecuritiesMaintainsBuy$620.00
October 22, 2025Wells FargoMaintainsOverweight$600.00
October 22, 2025BTIGMaintainsBuy$589.00
October 15, 2025Truist SecuritiesMaintainsBuy$525.00
October 13, 2025BTIGMaintainsBuy$529.00
October 7, 2025Evercore ISI GroupMaintainsIn-Line$450.00
October 1, 2025BTIGReiteratesBuy$571.00

U.S. procedure growth sustainability amid insurance and healthcare policy headwinds

Bull case

Goldman Sachs maintains a Buy rating with a $558 price target, arguing that investor fears around U.S. procedure growth are misplaced. The bank models only a modest 1% annual decline in U.S. revenue per procedure, pointing to Q1 2026's 17% total procedure volume growth and 23% revenue increase as evidence of durable underlying demand.

Bear case

ISRG shares dropped over 12% following Q2 2026 earnings, with investors alarmed by slowing U.S. procedure growth and a cautious company outlook. Concerns over insurance headwinds and potential Obamacare-related medtech demand disruption have driven Deutsche Bank to slash its target to $366, reflecting deep skepticism about near-term U.S. volume momentum.

Competitive pressure from emerging robotic surgery rivals

Bull case

Goldman Sachs and Bernstein both maintain Outperform ratings, viewing Intuitive Surgical's da Vinci 5 platform — with over 100 system enhancements — as a strong competitive moat. Bernstein's $685 price target reflects confidence that continuous product innovation keeps Intuitive well ahead of challengers in the robotic surgery market.

Bear case

Oppenheimer highlights rising competitive pressure and long-term pricing risks for Intuitive Surgical, as Medtronic's Hugo system and Johnson & Johnson's OTTAVA robot push harder into robotic surgery. These emerging rivals threaten to erode Intuitive's historically dominant market share and compress instrument pricing over time.

Impact of GLP-1 weight-loss drugs on surgical procedure volumes

Bull case

RBC sees Intuitive Surgical maintaining durable growth despite temporary U.S. headwinds, with the broader procedure mix — including colorectal, hernia, and cardiac applications — providing diversification beyond bariatric surgery. Strong Q1 2026 results with 17% procedure volume growth suggest GLP-1 impacts remain contained to a narrow procedure subset.

Bear case

Bariatric surgery volumes have already fallen approximately 10% as GLP-1 weight-loss drugs reduce demand for weight-related procedures. Analysts warn this structural shift could accelerate, meaningfully reducing a historically important volume driver for da Vinci procedures and pressuring Intuitive Surgical's overall U.S. growth trajectory going forward.